Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Prostate Cancer

Free Subscription 03.10.2022 1 BMC Cancer 1 Cancer 1 Cancer Lett 3 Eur Urol 2 Int J Radiat Oncol Biol Phys 1 Int J Urol 2 Nat Rev Urol 2 Prog Urol 4 Prostate 1 Ther Adv Urol 3 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. OLOKPA E, Mandape SN, Pratap S, Stewart MV, et al
   Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.
   BMC Cancer. 2022;22:1025.
   PubMed         Abstract available
   
   

   
   Cancer

2. 
   Men with prostate cancer at higher risk of venous thromboembolism.
   Cancer. 2022;128:3585.
   PubMed        
   
   

   
   Cancer Lett

3. LIU J, Dong L, Zhu Y, Dong B, et al
   Prostate cancer treatment - China's perspective.
   Cancer Lett. 2022 Sep 23:215927. doi: 10.1016/j.canlet.2022.215927.
   PubMed         Abstract available
   
   

   
   Eur Urol

4. DEVOS G, Tosco L, Baldewijns M, Gevaert T, et al
   ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
   Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02638.
   PubMed         Abstract available
   
   
5. SCHILHAM MGM, Rijpkema M, Scheenen T, Hermsen R, et al
   How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come.
   Eur Urol. 2022 Sep 24. pii: S0302-2838(22)02634.
   PubMed         Abstract available
   
   
6. SASSI H, Caron O, Rouleau E
   Re: Kara N. Maxwell, Heather H. Cheng, Jacquelyn Powers, et al. Inherited TP53 Variants and Risk of Prostate Cancer. Eur Urol 2022;81:243-50: Off-core Li-Fraumeni Syndrome Spectrum Cancers: Increasing Interest for Prostate Cancer?
   Eur Urol. 2022 Sep 21. pii: S0302-2838(22)02632.
   PubMed        
   
   

   
   Int J Radiat Oncol Biol Phys

7. BARNETT GC, Kerns SL, Dorling L, Fachal L, et al
   No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
   Int J Radiat Oncol Biol Phys. 2022;114:494-501.
   PubMed         Abstract available
   
   
8. PATEL SA, Ma TM, Wong JK, Stish BJ, et al
   External Beam Radiotherapy With or Without Brachytherapy Boost in Men with Very High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis.
   Int J Radiat Oncol Biol Phys. 2022 Sep 27. pii: S0360-3016(22)03399.
   PubMed         Abstract available
   
   

   
   Int J Urol

9. YAMAMOTO Y, Ishii M, Yoshimura A, Hayashi T, et al
   Efficacy of cabazitaxel in patients with metastatic castration-resistant prostate cancer: A single-center study in Japan.
   Int J Urol. 2022 Sep 28. doi: 10.1111/iju.15052.
   PubMed         Abstract available
   
   

   
   Nat Rev Urol

10. BARRETT T, de Rooij M, Giganti F, Allen C, et al
    Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway.
    Nat Rev Urol. 2022 Sep 27. pii: 10.1038/s41585-022-00648.
    PubMed         Abstract available
    
    
11. DE LA CALLE CM, Shee K, Yang H, Lonergan PE, et al
    The endoplasmic reticulum stress response in prostate cancer.
    Nat Rev Urol. 2022 Sep 27. pii: 10.1038/s41585-022-00649.
    PubMed         Abstract available
    
    

    
    Prog Urol

12. MANOLACHE NG, Mjaess G, Diamand R, Albisinni S, et al
    [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].
    Prog Urol. 2022 Sep 13. pii: S1166-7087(22)00396.
    PubMed         Abstract available
    
    
13. MRAD DALI K, Rahoui M, Chaker K, Ouanes Y, et al
    Positive urine culture prior to transrectal prostate biopsy was not associated with infectious complications development.
    Prog Urol. 2022;32:830-835.
    PubMed         Abstract available
    
    

    
    Prostate

14. LEE YHA, Hui JMH, Chan JSK, Liu K, et al
    Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
    Prostate. 2022 Sep 30. doi: 10.1002/pros.24443.
    PubMed         Abstract available
    
    
15. MUSTAFFA A, Emara S
    Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24444.
    PubMed         Abstract available
    
    
16. URABE F, Miki K, Kimura T, Sasaki H, et al
    Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24445.
    PubMed         Abstract available
    
    
17. WANG S, Zhang C, Xu Z, Chen MH, et al
    Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
    Prostate. 2022 Sep 26. doi: 10.1002/pros.24441.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

18. BANERJEE V, Wang S, Drescher M, Russell R, et al
    Radiogenomics influence on the future of prostate cancer risk stratification.
    Ther Adv Urol. 2022;14:17562872221125317.
    PubMed         Abstract available
    
    

    
    Urology

19. CHOE S, Patel HD, Lanzotti N, Okabe Y, et al
    MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection.
    Urology. 2022 Sep 21. pii: S0090-4295(22)00806.
    PubMed         Abstract available
    
    
20. INOUYE BM, Krischak MK, Krughoff K, Boysen WR, et al
    Resection of Pubic Symphysis and Cystectomy Significantly Improves Short-Term Patient-Reported Physical Functioning Among Patients With Pubovesical Fistula and Pubic Bone Osteomyelitis.
    Urology. 2022;167:218-223.
    PubMed         Abstract available
    
    
21. MOVASSAGHI M, Ahmed F, Patel H, Luk L, et al
    Association of Patient and Imaging-Related Factors With False Negative MRI-Targeted Prostate Biopsies of Suspicious PI-RADS 4 and 5 Lesions.
    Urology. 2022;167:165-170.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: